Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R130 in relapsed/refractory advanced solid tumors
NCT05886075Phase 1Unknown
- Sponsor
- Shanghai Yunying Medical Technology Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R130 in solid tumor (advanced stage), sponsored by Shanghai Yunying Medical Technology Co., Ltd. Primary endpoints: Subject incidence of adverse events at 6 months, Subject incidence of laboratory abnormalities at 1 month and 1 more. Status: unknown.
02
Drugs
R130
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05886075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886075.